Janux Therapeutics, Inc. (NASDAQ: JANX) has just announced positive updated interim clinical data for its janx007 clinical program, showing substantial activity in patients with 5th line metastatic castration-resistant prostate cancer (mCRPC). The data, as of November 15, 2024, revealed impressive results, with 100% of patients achieving the best PSA50 declines, 63% achieving the best PSA90 declines, and 31% achieving the best PSA99 declines.
Moreover, the durability of PSA declines was observed, with 75% of patients maintaining PSA50 declines and 50% maintaining PSA90 declines at 12 weeks or more. In terms of anti-tumor activity, 50% of patients showed a confirmed partial response, while 63% demonstrated disease control.
The safety profile of janx007 was also encouraging, with cytokine release syndrome (CRS) and treatment-related adverse events primarily limited to cycle 1 and grades 1 and 2. Notably, the maximum tolerable dose for janx007 has not yet been reached.
Based on these compelling efficacy and safety results, Janux has identified two once-weekly step dose regimens for phase 1b expansion trials targeting pre-pluvicto® 2L and 3L patients. The company anticipates providing another update on janx007 in 2025.
Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific membrane antigen (PSMA), and janx008, which targets epidermal growth factor receptor (EGFR). These candidates are being studied in phase 1 clinical trials for mCRPC and multiple solid cancers, respectively.
As a result of these announcements, the company's shares have moved -11.1% on the market, and are now trading at a price of $40.18. For more information, read the company's full 8-K submission here.
